| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2003-09-3080 |
| P698 | PubMed publication ID | 14645001 |
| P50 | author | Liliana Devizzi | Q42435704 |
| Daniele Mattei | Q52856332 | ||
| Umberto Vitolo | Q56998074 | ||
| Massimo Federico | Q57031724 | ||
| Francesco Zaja | Q57307002 | ||
| Massimo Federico | Q57417821 | ||
| P2093 | author name string | Caterina Stelitano | |
| Emilio Iannitto | |||
| Fortunato Morabito | |||
| Luigi Rigacci | |||
| Maurizio Martelli | |||
| Andrea Gallamini | |||
| Ercole Brusamolino | |||
| Intergruppo Italiano Linfomi | |||
| Maura Brugiatelli | |||
| Sergio Cortelazzo | |||
| Monica Bellei | |||
| Roberta Calvi | |||
| Gino Santini | |||
| Giuseppe Todeschini | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | peripheral T-cell lymphoma | Q7168693 |
| P304 | page(s) | 2474-2479 | |
| P577 | publication date | 2003-11-26 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study | |
| P478 | volume | 103 |
| Q85610833 | A case of peripheral T-cell lymphoma presenting with acute liver failure |
| Q43011827 | A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score |
| Q48365219 | A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas |
| Q40444551 | A prospective cohort study of patients with peripheral T-cell lymphoma in the United States |
| Q35931553 | A rare case of peripheral T-cell lymphoma in 1-year-old child. |
| Q87022506 | A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group |
| Q39608513 | Activation of T-cell receptor signaling in peripheral T-cell lymphoma cells plays an important role in the development of lymphoma-associated hemophagocytosis. |
| Q94550714 | Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial |
| Q36231758 | Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control |
| Q41215812 | An update in management of noncutaneous T-cell lymphomas |
| Q35683871 | An update on the management of peripheral T-cell lymphoma and emerging treatment options |
| Q40166880 | Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma |
| Q39551660 | Atypical presentation of isolated peripheral T-cell lymphoma in the hand: case report |
| Q36907048 | Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis |
| Q58701502 | B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma |
| Q60907239 | Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma |
| Q37579991 | Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma. |
| Q53457702 | Bizarre‐looking violaceous nodular plaque on the hands: Unusual presentation of peripheral T‐cell lymphoma, not otherwise specified |
| Q41246604 | CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin |
| Q48920072 | Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies: a single-institution study of 225 cases |
| Q42283444 | Clinical characteristics of angioimmunoblastic T-cell lymphoma in China and C-reactive protein as an independent prognostic factor |
| Q40344267 | Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience |
| Q40791381 | Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan |
| Q47769416 | Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis |
| Q48608139 | Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. |
| Q92683898 | Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma |
| Q43985167 | Clinical significance of jejunoileal involvement of non-Hodgkin's lymphoma detected by double-balloon enteroscopy |
| Q36591293 | Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials |
| Q46658608 | Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas |
| Q36494259 | Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project |
| Q47757848 | Clinicopathological analysis in PTCL-NOS with CADM1 expression |
| Q43281535 | Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China |
| Q93088267 | Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma, Not Otherwise Specified |
| Q33428567 | Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study |
| Q55135232 | Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. |
| Q83388959 | Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma |
| Q35533531 | Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease |
| Q36156508 | Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. |
| Q26998446 | Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective |
| Q38187365 | Current role of FDG PET/CT in lymphoma |
| Q36716218 | Decreased apolipoprotein A-I level indicates poor prognosis in extranodal natural killer/T-cell lymphoma, nasal type. |
| Q37331991 | Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting |
| Q44305871 | Diagnostic impact of molecular lineage analysis on paraffin-embedded tissue in hematolymphoid neoplasia reclassified by current WHO criteria |
| Q87775140 | Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry |
| Q53304621 | Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity |
| Q90510592 | Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG) |
| Q35064709 | Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma |
| Q35040638 | Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders |
| Q50562057 | Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. |
| Q91184022 | Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma |
| Q36612584 | Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyond |
| Q54560297 | Expansion of NKG2C-expressing Natural Killer Cells after Umbilical Cord Blood Transplantation in a Patient with Peripheral T-cell Lymphoma with Cytotoxic Molecules. |
| Q36594091 | Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type |
| Q36873318 | Flow cytometric characterization and clinical outcome of CD4+ T-cell lymphoma in dogs: 67 cases. |
| Q30275251 | Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas |
| Q33585286 | GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features |
| Q35629006 | Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets |
| Q97423469 | Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine |
| Q37303846 | Hematopoietic SCT for peripheral T-cell lymphoma |
| Q37122302 | Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma |
| Q36604739 | High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors |
| Q44525952 | High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis |
| Q35865090 | How I treat the peripheral T-cell lymphomas |
| Q36355093 | How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models? |
| Q38256603 | Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma |
| Q38824662 | Human T-cell leukemia virus-associated malignancy |
| Q93026747 | Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis |
| Q38345572 | Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. |
| Q36289029 | Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis |
| Q41928592 | Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas |
| Q92463729 | Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma |
| Q90734247 | Indolent T-cell lymphoproliferative disorder of the stomach successfully treated by radiotherapy |
| Q33750759 | Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience |
| Q33390353 | Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma |
| Q37454524 | Intestinal T-cell lymphomas: a retrospective analysis of 68 cases in China |
| Q38300780 | Jejunocolic fistula associated with an intestinal T cell lymphoma |
| Q33745878 | Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant |
| Q36809448 | Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas |
| Q35207251 | Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy |
| Q37625441 | Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. |
| Q37738501 | Management of advanced-stage peripheral T-cell lymphomas |
| Q33634415 | Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma |
| Q27026081 | New molecular insights into peripheral T cell lymphomas |
| Q51402406 | Nodular lymphocyte-predominant hodgkin lymphoma with atypical T cells: a morphologic variant mimicking peripheral T-cell lymphoma. |
| Q35789262 | Non-Hodgkin lymphoma: an update |
| Q37244708 | Novel therapies in peripheral T-cell lymphomas |
| Q37738622 | Novel therapies in peripheral T-cell lymphomas |
| Q47306867 | Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers |
| Q41942675 | Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies. |
| Q41637945 | Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report |
| Q92495655 | Peripheral T cell lymphoma coexisting with Castleman's disease: A case report and literature review |
| Q55000262 | Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) presenting as an endobronchial lesion: Case report and literature review. |
| Q52577773 | Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. |
| Q37255632 | Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. |
| Q60019708 | Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India |
| Q35215271 | Peripheral T cell lymphoma: not otherwise specified |
| Q37641113 | Peripheral T-cell lymphoma presenting as an ischemic stroke in a 23-year-old woman: a case report and review of the literature |
| Q58803558 | Peripheral T-cell lymphoma, not otherwise specified, presenting with generalized ulcerated plaques and hypereosinophilia |
| Q37777597 | Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy |
| Q34479082 | Peripheral T-cell lymphoma: review and updates of current management strategies |
| Q37020399 | Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review |
| Q38852024 | Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study |
| Q33433565 | Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients. |
| Q45324002 | Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. |
| Q36038466 | Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified: A Rapidly Progressive Variant of Cutaneous T-Cell Lymphoma. |
| Q35697053 | Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations. |
| Q35978602 | Primary orbital non-Hodgkin's lymphoma |
| Q35224833 | Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas |
| Q97423465 | Prognostic Nutritional Index, Another Prognostic Factor for Extranodal Natural Killer/T Cell Lymphoma, Nasal Type |
| Q84459030 | Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients |
| Q34166857 | Prognostic markers in peripheral T-cell lymphoma |
| Q64075909 | Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma |
| Q41913876 | Prognostic significance of [18F]fluorodeoxyglucose-positron emission tomography in peripheral T-cell lymphoma treated with stem cell transplantation: a retrospective analysis |
| Q60914254 | Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis |
| Q53594239 | Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. |
| Q41568274 | Pulmonary involvement of peripheral T-cell lymphoma manifesting as crazy paving pattern. |
| Q40102773 | Rapid Evolving Unilateral Indurated Oozing Facial Plaques in a Patient with Head-and-Neck Cancer: Peripheral T-Cell Lymphoma Not Otherwise Specified (NOS). |
| Q41607082 | Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy |
| Q90371655 | Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas |
| Q90328377 | Refractory Septic Shock due to Underlying Immunocompromised Disease: A Case of Fatal Peripheral T-Cell Lymphoma Not Otherwise Specified in a Young Hispanic Woman |
| Q90338521 | Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry |
| Q33579708 | Research progresses in the pathogenesis of anaplastic large cell lymphoma. |
| Q44150917 | Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. |
| Q42257030 | Reversion-inducing cysteine-rich protein with Kazal motifs gene expression and its clinical significance in peripheral T-cell lymphoma |
| Q64121292 | Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma |
| Q26785732 | Romidepsin for the Treatment of Peripheral T-Cell Lymphoma |
| Q39659168 | Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified |
| Q81557250 | Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U) |
| Q33822764 | Should Eligible Patients with T-Cell Lymphoma Receive High-Dose Therapy and Autologous Stem Cell Transplant in the Upfront Setting? |
| Q38046051 | Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: no... well yes, ...but maybe not for long |
| Q37560801 | Significance of clinical factors as prognostic indicators for patients with peripheral T-cell non-Hodgkin lymphoma: A retrospective analysis of 252 cases |
| Q35685336 | Survival in patients with limited-stage peripheral T-cell lymphomas |
| Q39092818 | T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes |
| Q37763879 | Targeted treatment and new agents in peripheral T-cell lymphoma |
| Q37653274 | The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. |
| Q30401307 | The Comparative Diagnostic Features of Canine and Human Lymphoma |
| Q38602677 | The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project |
| Q52656022 | The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. |
| Q33702181 | The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas |
| Q40421573 | The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. |
| Q99551876 | Treatment approaches in relapsed or refractory peripheral T-cell lymphomas |
| Q46871894 | Treatment of peripheral T cell lymphoma with an intensive protocol ACEP (adriamycin, cyclophosphamide, etoposide and prednisolone) and ifosfamide showing an important response and overall survival rates |
| Q30613674 | Treatment of peripheral T-cell lymphoma: are we data driven or driving the data? |
| Q48517926 | Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma |
| Q37738560 | Update on the World Health Organization classification of peripheral T-cell lymphomas |
| Q37939715 | Update: peripheral T-cell lymphomas |
| Q90171240 | Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making |
| Q85509695 | [Clinical analysis of 25 patients with aggressive peripheral T-cell lymphoma in advanced stage treated with autologous stem cell transplantation] |
| Q89762552 | [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy] |
| Q88739413 | [Prognostic value of lymphocyte-to-monocyte ratio in angioimmunoblastic T cell lymphoma] |
| Q90087562 | nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified |
Search more.